Skip to content
lsd.com
TerminatedPhase 1

Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder

NCT05322954 · University of Wisconsin, Madison

Closed to entry
Status
Not accepting participants
Phase 1
Phase
5
Target enrolment
1
Study sites
1 US states

What it is testing

Summary

The purpose of this research study is to investigate the safety and feasibility of two (2) oral doses of psilocybin when combined with behavioral support for methamphetamine use disorder (MUD). Participants have a diagnosis of methamphetamine use disorder (MUD). Participants can expect to be actively engaged in the study for up to 26 weeks.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Incidence of serious adverse events associated with oral psilocybin

    Measured over Up to 26 weeks

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

25 Years to 65 Years
Ages
All
Sex
Not accepted
Healthy volunteers
Inclusion Criteria: * Diagnosis of methamphetamine use disorder Exclusion Criteria: * Positive urine pregnancy at any time point during screening or study participation * Inadequately treated hypertension, defined as 2 blood pressure readings, 10 minutes apart, of greater than 140/90 mmHg systolic/diastolic * Current acute coronary syndrome or angina * History of heart transplant or stroke * Current use of and inability or unwillingness to taper off of medications that may interact with psilocybin * Current insulin dependence, due to Type I or Type II diabetes

Where

1 study site

FacilityCityRegionCountry
University of WisconsinMadisonWisconsinUnited States

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT05322954 on ClinicalTrials.gov →

Last updated in the registry 2026-05-12. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits

Substance

Recruiting in

All 10 trials from University of Wisconsin, Madison →